The Asia Pacific Lymphoma Therapeutics Market should witness market growth of 8.2% CAGR during the forecast period (2023-2029).
The etiology of the majority of lymphoma cases remains unknown. However, certain individuals are deemed to be at an elevated risk. These individuals have immunodeficiency, which may be a result of a weakened immune system due to HIV or the use of an immune system-suppressing medication following an organ transplant. In addition, individuals diagnosed with specific autoimmune conditions, like celiac disease and rheumatoid arthritis, are at a heightened risk for developing lymphoma.
The incidence of lymphoma tends to increase with age. Certain types are prevalent among young children and infants. The incidence of lymphoma is gender-biased, with men being at a higher risk than women. However, certain subtypes of NHL have a higher propensity to manifest in women. Individuals who have contracted infections such as HTLV-1, H. pylori, hepatitis C, or EBV are linked to a higher risk.
Individuals who come into contact with chemicals present in fertilizers, pesticides, and herbicides are more prone to it. Exposure to nuclear radiation may elevate the likelihood of developing NHL. Obesity can increase the likelihood of lymphoma development in individuals. Having a sibling diagnosed with this kind of cancer increases the risk of developing it. Mononucleosis can be caused by an EBV infection. This condition may elevate the likelihood of developing lymphoma.
In India, there are notable differences in the demographic and clinical characteristics of patients with lymphoma when compared to developed nations. These differences include a lower median age of 54 years, a higher male-to-female ratio, a higher proportion of patients with B-symptoms. Also, they have a poor ECOG performance status at diagnosis, a higher frequency of diffuse large B-cell lymphomas, a lower frequency of follicular NHL, and a higher frequency of T-cell type. In addition, the mortality rate attributed to NHL is comparatively higher in India as compared to other regions of the world. Hence, the high cases of non-Hodgkin's lymphoma will increase the demand for numerous therapeutic methods for its treatment and thereby propel the market growth of lymphoma therapeutics in APAC.
The China market dominated the Asia Pacific Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,818.6 million by 2029. The Japan market is estimated to grow a CAGR of 7.6% during (2023-2029). Additionally, The India market would experience a CAGR of 8.9% during (2023-2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
The etiology of the majority of lymphoma cases remains unknown. However, certain individuals are deemed to be at an elevated risk. These individuals have immunodeficiency, which may be a result of a weakened immune system due to HIV or the use of an immune system-suppressing medication following an organ transplant. In addition, individuals diagnosed with specific autoimmune conditions, like celiac disease and rheumatoid arthritis, are at a heightened risk for developing lymphoma.
The incidence of lymphoma tends to increase with age. Certain types are prevalent among young children and infants. The incidence of lymphoma is gender-biased, with men being at a higher risk than women. However, certain subtypes of NHL have a higher propensity to manifest in women. Individuals who have contracted infections such as HTLV-1, H. pylori, hepatitis C, or EBV are linked to a higher risk.
Individuals who come into contact with chemicals present in fertilizers, pesticides, and herbicides are more prone to it. Exposure to nuclear radiation may elevate the likelihood of developing NHL. Obesity can increase the likelihood of lymphoma development in individuals. Having a sibling diagnosed with this kind of cancer increases the risk of developing it. Mononucleosis can be caused by an EBV infection. This condition may elevate the likelihood of developing lymphoma.
In India, there are notable differences in the demographic and clinical characteristics of patients with lymphoma when compared to developed nations. These differences include a lower median age of 54 years, a higher male-to-female ratio, a higher proportion of patients with B-symptoms. Also, they have a poor ECOG performance status at diagnosis, a higher frequency of diffuse large B-cell lymphomas, a lower frequency of follicular NHL, and a higher frequency of T-cell type. In addition, the mortality rate attributed to NHL is comparatively higher in India as compared to other regions of the world. Hence, the high cases of non-Hodgkin's lymphoma will increase the demand for numerous therapeutic methods for its treatment and thereby propel the market growth of lymphoma therapeutics in APAC.
The China market dominated the Asia Pacific Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,818.6 million by 2029. The Japan market is estimated to grow a CAGR of 7.6% during (2023-2029). Additionally, The India market would experience a CAGR of 8.9% during (2023-2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
Scope of the Study
By Treatment Type
- Immune Therapy
- Target Therapy
- Chemotherapy
- Radiation Therapy
By Disease Type
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
By Route of Administration
- Injectable
- Oral Route
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Company
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences, Inc.
- Seagen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Eli Lilly And Company
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Lymphoma Therapeutics Market, by Treatment Type
1.4.2 Asia Pacific Lymphoma Therapeutics Market, by Disease Type
1.4.3 Asia Pacific Lymphoma Therapeutics Market, by Route of Administration
1.4.4 Asia Pacific Lymphoma Therapeutics Market, by Distribution Channel
1.4.5 Asia Pacific Lymphoma Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Analyst's Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Asia Pacific Lymphoma Therapeutics Market by Treatment Type
4.1 Asia Pacific Immune Therapy Market by Country
4.2 Asia Pacific Target Therapy Market by Country
4.3 Asia Pacific Chemotherapy Market by Country
4.4 Asia Pacific Radiation Therapy Market by Country
Chapter 5. Asia Pacific Lymphoma Therapeutics Market by Disease Type
5.1 Asia Pacific Non-Hodgkin Lymphoma Market by Country
5.2 Asia Pacific Hodgkin Lymphoma Market by Country
Chapter 6. Asia Pacific Lymphoma Therapeutics Market by Route of Administration
6.1 Asia Pacific Injectable Market by Country
6.2 Asia Pacific Oral Route Market by Country
Chapter 7. Asia Pacific Lymphoma Therapeutics Market by Distribution Channel
7.1 Asia Pacific Hospital Pharmacies Market by Country
7.2 Asia Pacific Retail Pharmacies Market by Country
7.3 Asia Pacific Others Market by Country
Chapter 8. Asia Pacific Lymphoma Therapeutics Market by Country
8.1 China Lymphoma Therapeutics Market
8.1.1 China Lymphoma Therapeutics Market by Treatment Type
8.1.2 China Lymphoma Therapeutics Market by Disease Type
8.1.3 China Lymphoma Therapeutics Market by Route of Administration
8.1.4 China Lymphoma Therapeutics Market by Distribution Channel
8.2 Japan Lymphoma Therapeutics Market
8.2.1 Japan Lymphoma Therapeutics Market by Treatment Type
8.2.2 Japan Lymphoma Therapeutics Market by Disease Type
8.2.3 Japan Lymphoma Therapeutics Market by Route of Administration
8.2.4 Japan Lymphoma Therapeutics Market by Distribution Channel
8.3 India Lymphoma Therapeutics Market
8.3.1 India Lymphoma Therapeutics Market by Treatment Type
8.3.2 India Lymphoma Therapeutics Market by Disease Type
8.3.3 India Lymphoma Therapeutics Market by Route of Administration
8.3.4 India Lymphoma Therapeutics Market by Distribution Channel
8.4 South Korea Lymphoma Therapeutics Market
8.4.1 South Korea Lymphoma Therapeutics Market by Treatment Type
8.4.2 South Korea Lymphoma Therapeutics Market by Disease Type
8.4.3 South Korea Lymphoma Therapeutics Market by Route of Administration
8.4.4 South Korea Lymphoma Therapeutics Market by Distribution Channel
8.5 Singapore Lymphoma Therapeutics Market
8.5.1 Singapore Lymphoma Therapeutics Market by Treatment Type
8.5.2 Singapore Lymphoma Therapeutics Market by Disease Type
8.5.3 Singapore Lymphoma Therapeutics Market by Route of Administration
8.5.4 Singapore Lymphoma Therapeutics Market by Distribution Channel
8.6 Malaysia Lymphoma Therapeutics Market
8.6.1 Malaysia Lymphoma Therapeutics Market by Treatment Type
8.6.2 Malaysia Lymphoma Therapeutics Market by Disease Type
8.6.3 Malaysia Lymphoma Therapeutics Market by Route of Administration
8.6.4 Malaysia Lymphoma Therapeutics Market by Distribution Channel
8.7 Rest of Asia Pacific Lymphoma Therapeutics Market
8.7.1 Rest of Asia Pacific Lymphoma Therapeutics Market by Treatment Type
8.7.2 Rest of Asia Pacific Lymphoma Therapeutics Market by Disease Type
8.7.3 Rest of Asia Pacific Lymphoma Therapeutics Market by Route of Administration
8.7.4 Rest of Asia Pacific Lymphoma Therapeutics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Bayer AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Approvals and Trials:
9.1.6 SWOT Analysis
9.2 Johnson & Johnson
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental &Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 Gilead Sciences, Inc.
9.3.1 Company overview
9.3.2 Financial Analysis
9.3.3 Research & Development Expenses
9.3.4 Recent strategies and developments:
9.3.4.1 Partnerships, Collaborations, and Agreements:
9.3.4.2 Acquisition and Mergers:
9.3.4.3 Approvals and Trials:
9.4 Bristol Myers Squibb Company
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Acquisition and Mergers:
9.4.5.2 Approvals and Trials:
9.5 Pfizer, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional & Segmental Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.5.5.2 Approvals and Trials:
9.6 AstraZeneca PLC
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Acquisition and Mergers:
9.6.5.3 Approvals and Trials:
9.7 Teva Pharmaceutical Industries Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.8 Eli Lilly And Company
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Acquisition and Mergers:
9.8.5.2 Approvals and Trials:
9.9 Seagen, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals and Trials:
9.10. F. Hoffmann-La Roche Ltd.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
Companies Mentioned
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences, Inc.
- Seagen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Eli Lilly And Company
Methodology
LOADING...
